Shots:

• The ongoing P-I/IIa sub-study involves evaluating safety- reactogenicity & immunogenicity of COVID-19 vaccine (IM- given as single-dose or two-dose- 8 wks. apart) in adults across multiple clinical sites in Belgium & the US
• The results demonstrated durable humoral & cellular immune responses in single-shot COVID-19 vaccine @8mos. after immunization & elicits neutralizing Ab activity against Delta variant (B.1.617.2) & other SARS-CoV-2 variants of concern
• The results from a new analysis of blood samples in the P-III ENSEMBLE study showed that the single-shot COVID-19 vaccine- induced neutralizing Ab activity against the Delta variant at a higher level

  Ref: J&J | Image: Actualidad RT